169 related articles for article (PubMed ID: 30348020)
1. Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells.
Pindiprolu SKSS; Chintamaneni PK; Krishnamurthy PT; Ratna Sree Ganapathineedi K
Drug Dev Ind Pharm; 2019 Feb; 45(2):304-313. PubMed ID: 30348020
[TBL] [Abstract][Full Text] [Related]
2. Phenyl boronic acid-modified lipid nanocarriers of niclosamide for targeting triple-negative breast cancer.
Ss Pindiprolu SK; Krishnamurthy PT; Ghanta VR; Chintamaneni PK
Nanomedicine (Lond); 2020 Jul; 15(16):1551-1565. PubMed ID: 32618501
[No Abstract] [Full Text] [Related]
3. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
Pindiprolu SKSS; Krishnamurthy PT; Dev C; Chintamaneni PK
Chem Phys Lipids; 2021 Mar; 235():105033. PubMed ID: 33385372
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
5. Octenylsuccinate hydroxypropyl phytoglycogen enhances the solubility and in-vitro antitumor efficacy of niclosamide.
Xie Y; Yao Y
Int J Pharm; 2018 Jan; 535(1-2):157-163. PubMed ID: 29113805
[TBL] [Abstract][Full Text] [Related]
6. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and
Darabi F; Saidijam M; Nouri F; Mahjub R; Soleimani M
Biomed Res Int; 2022; 2022():6253978. PubMed ID: 35845934
[TBL] [Abstract][Full Text] [Related]
8. Curcumin-Loaded Solid Lipid Nanoparticles Enhanced Anticancer Efficiency in Breast Cancer.
Wang W; Chen T; Xu H; Ren B; Cheng X; Qi R; Liu H; Wang Y; Yan L; Chen S; Yang Q; Chen C
Molecules; 2018 Jun; 23(7):. PubMed ID: 29966245
[TBL] [Abstract][Full Text] [Related]
9. Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line.
Bhatt H; Rompicharla SVK; Komanduri N; Aashma S; Paradkar S; Ghosh B; Biswas S
Curr Drug Deliv; 2018; 15(9):1271-1283. PubMed ID: 29732970
[TBL] [Abstract][Full Text] [Related]
10. Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro.
Eskiler GG; Cecener G; Dikmen G; Egeli U; Tunca B
Curr Drug Deliv; 2019; 16(6):511-529. PubMed ID: 31113350
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, and anti-tumor property of podophyllotoxin-loaded solid lipid nanoparticles.
Zhu RR; Qin LL; Wang M; Wu SM; Wang SL; Zhang R; Liu ZX; Sun XY; Yao SD
Nanotechnology; 2009 Feb; 20(5):055702. PubMed ID: 19417361
[TBL] [Abstract][Full Text] [Related]
12. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
[TBL] [Abstract][Full Text] [Related]
13. Formulation optimization, characterization, and evaluation of in vitro cytotoxic potential of curcumin loaded solid lipid nanoparticles for improved anticancer activity.
Rompicharla SVK; Bhatt H; Shah A; Komanduri N; Vijayasarathy D; Ghosh B; Biswas S
Chem Phys Lipids; 2017 Nov; 208():10-18. PubMed ID: 28842128
[TBL] [Abstract][Full Text] [Related]
14. Clathrin-mediated endocytic uptake of PUFA enriched self-nanoemulsifying lipidic systems (SNELS) of an anticancer drug against triple negative cancer and DMBA induced preclinical tumor model.
Khurana RK; Kumar R; Gaspar BL; Welsby G; Welsby P; Kesharwani P; Katare OP; Singh KK; Singh B
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():645-658. PubMed ID: 30033299
[TBL] [Abstract][Full Text] [Related]
15. Vitamin E TPGS Emulsified Vinorelbine Bitartrate Loaded Solid Lipid Nanoparticles (SLN): Formulation Development, Optimization and In vitro Characterization.
Maurya L; Singh S; Rajamanickam VM; Narayan G
Curr Drug Deliv; 2018; 15(8):1135-1145. PubMed ID: 29629662
[TBL] [Abstract][Full Text] [Related]
16. Application of quality-by-design approach to optimize diallyl disulfide-loaded solid lipid nanoparticles.
Talluri SV; Kuppusamy G; Karri VV; Yamjala K; Wadhwani A; Madhunapantula SV; Pindiprolu SS
Artif Cells Nanomed Biotechnol; 2017 May; 45(3):474-488. PubMed ID: 27112220
[TBL] [Abstract][Full Text] [Related]
17. Solid lipid nanoparticles of Annona muricata fruit extract: formulation, optimization and in vitro cytotoxicity studies.
Sabapati M; Palei NN; C K AK; Molakpogu RB
Drug Dev Ind Pharm; 2019 Apr; 45(4):577-586. PubMed ID: 30663427
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles.
Lee MK; Lim SJ; Kim CK
Biomaterials; 2007 Apr; 28(12):2137-46. PubMed ID: 17257668
[TBL] [Abstract][Full Text] [Related]
19. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
[TBL] [Abstract][Full Text] [Related]
20. Formulation, characterization, and in vitro/vivo studies of aclacinomycin A-loaded solid lipid nanoparticles.
Jia Y; Ji J; Wang F; Shi L; Yu J; Wang D
Drug Deliv; 2016 May; 23(4):1317-25. PubMed ID: 25371296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
